ANOKION
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.
ANOKION
Social Links:
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2010-01-01
Address:
Ecublens, Vaud, Switzerland
Country:
Switzerland
Website Url:
http://www.anokion.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
112.61 M USD
Technology used in webpage:
Euro U.S. Server Location Cogent Communications
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2019-09-11 | Kanyos Bio | Kanyos Bio acquired by Anokion | N/A |
Investors List
Pfizer Breakthrough Growth Initiative
Pfizer Breakthrough Growth Initiative investment in Venture Round - Anokion
Versant Ventures
Versant Ventures investment in Series B - Anokion
Novo Ventures
Novo Ventures investment in Series B - Anokion
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Anokion
Celgene
Celgene investment in Series B - Anokion
André J. Mueller
André J. Mueller investment in Series A - Anokion
Novo Ventures
Novo Ventures investment in Series A - Anokion
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Anokion
Versant Ventures
Versant Ventures investment in Series A - Anokion
Harry Welten
Harry Welten investment in Series A - Anokion
Official Site Inspections
http://www.anokion.com Semrush global rank: 3.15 M Semrush visits lastest month: 4.77 K
- Host name: cloudproxy10011.sucuri.net
- IP address: 192.124.249.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Anokion"
Anokion - Crunchbase Company Profile & Funding
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the …See details»
About Us – Anokion
Toggle navigation. About Us . Overview; Leadership Team; Board of Directors; Science & Platform . What is Immune Tolerance?See details»
Anokion - Funding, Financials, Valuation & Investors - Crunchbase
Sep 11, 2019 Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance. Search Crunchbase. Start Free Trial . ...See details»
Overview - Anokion
Anokion SA (including our wholly-owned subsidiaries Anokion US, Inc. and Kanyos Bio, Inc.) is focused on improving the treatment and outcomes of autoimmune disease. Our proprietary …See details»
Anokion Company Profile 2024: Valuation, Funding & Investors
Anokion General Information Description. Developer of antigen-specific immunotherapy designed to offer services for immune tolerance. The company's immunotherapy focuses on both …See details»
Anokion Company Profile - Office Locations, Competitors ... - Craft
Anokion has 5 employees across 2 locations and $77.61 m in total funding,. See insights on Anokion including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Anokion - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Anokion . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... About. Anokion has 6 current employee profiles, …See details»
Anokion - Company Profile - Tracxn
Nov 30, 2024 Anokion. has raised a total funding of $112M over 3 rounds. Its first funding round was on May 09, 2014. What are the most recent funding rounds of Anokion? Its latest funding …See details»
Anokion SA - Drug pipelines, Patents, Clinical trials - Synapse
Explore Anokion SA with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 29 news, and 2 literature, Disease Domain:Immune System Diseases, Endocrinology and …See details»
Anokion - Raised $112M Funding from 7 investors - Tracxn
Nov 19, 2024 List of Anokion's institutional investors. Pfizer, located in New York City (United States), made their first investment in Anokion on Oct 18, 2022 in its Series B round.; Celgene, …See details»
Beyond Celiac Drives Recruitment for Promising Anokion Clinical …
Nov 18, 2020 About Anokion Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring …See details»
Leadership Team - Anokion
Nicole Luosey, PMP Senior Vice President, Product and Development OperationsSee details»
Anokion Announces $35 Million Equity Investment from Pfizer
Oct 18, 2022 About Anokion Anokion SA is a clinical-stage Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune …See details»
Anokion Announces Leadership Team Expansion to Support …
Oct 27, 2022 About Anokion Anokion SA is a clinical-stage Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune …See details»
Pipeline – Anokion
The company is currently developing KAN-101 for the treatment of celiac disease. KAN-101 is an experimental therapy in early clinical development. Anokion is focused on enrolling and …See details»
Anokion Announces Publication in Science Immunology
Mar 1, 2021 Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal …See details»
Anokion Strengthens its Senior Leadership with Promotions and …
Sep 7, 2023 Cambridge, Mass. and Lausanne, Switzerland, September 7, 2023 – Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring …See details»
Anokion Announces Progress Across Pipeline of Novel …
Jan 6, 2022 Anokion SA is a clinical-stage Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring …See details»
Anokion Announces Publication in Science Immunology
Mar 1, 2021 Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the …See details»